Hormone replacement therapy and ischaemic heart disease among postmenopausal women

European Journal of Preventive Cardiology

Volumn 6, Issue 2, 1999, Pages 105-112

  Kardos, Attila ^a   Casadei, Barbara ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

hormone replacement therapy; ischaemic heart disease; menopause

Indexed keywords

ESTROGEN; INSULIN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; GLUCOSE METABOLISM; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MORBIDITY; MORTALITY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; LIPIDS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTERONE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84992849174     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748739900600207     Document Type: Article

References (91)

1. Eaker E, Chesebro JH, Sacks FM. Cardiovascular disease in women. Circulation 1993; 88: 1999–2009.
2. Sans A, Kesteloot H, Kromhout D. The burden of cardiovascular disease mortality in Europe. Task force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in Europe. Eur Heart J 1997; 18: 1231–1248.
3. Stampfer MJ, Colditz GA, Willet WC. Menopause and heart disease: a review. Ann NY Acad Sci 1989; 592: 193–203.
4. Christiansen C. Sex steroids and the cardiovascular system. Osteoporosis 1997; 7(suppl 1): S8–S11.
5. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38: 199–210.
6. World Heath Organization. World health statistics annual: vital statistics and causes of death 1980. Geneva: WHO; 1980.
7. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables in menopausal status: influence on hormone replacement therapy. Thromb Haemost 1993; 70: 584–587.
8. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641–646.
9. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183–1188.
10. Hamsten A, Wiman B, de-Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–1563.
11. Gebara OCE, Mittelman MA, Sutherland P, Lipinska I, Matheney T, Xu P, et al Association between increased oestrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952–1958.
12. Dallongeville J, Marecaux N, Isorez D, Zylberberg G, Fruchart JC, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995; 118: 123–133.
13. Lindheim SR, Vijod MA, Presser SC, Stanczyk FZ, Ditkoff EC, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60: 664–667.
14. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, et al Menopause is associated with endothelial dysfunction in women. Hypertension 1996; 28: 576–582.
15. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1–7.
16. Assman G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713–1724.
17. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–1204.
18. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG–low HDL cholesterol and LDL cholesterol to the incidence of ischaemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17: 1114–1120.
19. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–1109.
20. The writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199–208.
21. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595–601.
22. Plushner SL. Lipoprotein disorders in women; which women are the best candidates for hormone replacement therapy? Ann Pharmacother 1997; 30: 98–107.
23. Granfone A, Campos H, McNamara Jr., Schaefer MM, Lamon-Fava S, Orvodas JM, et al Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in post-menopausal, dyslipidemic women. Metabolism 1992; 41: 1193–1198.
24. Tikkanen MJ, Nikkila EA. Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women. Lancet 1978; 11: 490–492.
25. Denke MA. Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholesterolaemic postmenopausal women. Am J Med 1995; 99: 29–35.
26. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako, Waclawiw MA, et al Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemia postmenopausal women. Circulation 1999; 99: 354–360.
27. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, et al Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683–690.
28. Windier E, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem 1980; 255: 10464–10471.
29. Windier E, Kovanen PT, Chao YS, Havel RJ. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat: opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem 1980; 255: 8303–8307.
30. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149–1155.
31. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, et al Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032–2036.
32. Van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocystein in postmenopausal women. Eur J Clin Invest 1994; 24: 733–736.
33. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 1997; 78: 770–780.
34. Daly E, Vessey MP, Hawkins MH, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–980.
35. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–983.
36. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, et al Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–987.
37. Lorenzo C Varas, Rodriguez LA Garcia, Cattaruzzi C, Troncon MG, Agostinis L, Gutthann S Perez. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 147: 387–390.
38. Gutthann S Perez, Rodriguez LA Garcia, Castellsague J, Oliart A Duque. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796–800.
39. Hulley S, Grady G, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613.
40. Price DT, Ridker PM, Factor V Leiden mutation and the risk for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127: 895–903.
41. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990; 10: 531–534.
42. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993; 88: 2163–2171.
43. Brussaard HE, Leuven JA Gevers, Frölich M, Kluft C, Krans HMJ. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997 40: 843–849.
44. Kornhauser C, Malacara JM, Garay ME, Pérez-Luque EL. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J Hum Hypertens 1997; 11: 405–411.
45. Proudler AJ, Ahmed HAI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting enzyme activity in postmenopausal women. Lancet 1995; 346: 89–90.
46. Schunkert H, Danser AHJ, Hense HW, Derkx FHM, Kürzinger S, Riegger GAJ. Effects of estrogen replacement therapy on the renin–angiotensin system in postmenopausal women. Circulation 1997; 95: 39–45.
47. Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995; 99: 119–122.
48. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786–791.
49. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995; 75: 264–268.
50. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121: 936–941.
51. Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 839–842.
52. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992; 20: 452–457.
53. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81: 1680–1687.
54. Clarkson TB, Anthony MB, Potvin-Klein K. Effects of estrogen treatment on arterial wall structure and function. Drugs 1994; 47: 42–51.
55. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, et a l17 Beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92: 24–30.
56. Miyagawa K, Rösch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324–327.
57. Shemesh J, Frenkel Y, Leibovitch L, Grossman E, Pines A, Motro M. Does hormone replacement therapy inhibit coronary artery calcification? Obstet Gynecol 1997; 89: 989–992.
58. Fogelberg M, Vesterquist O, Diczfalusi U, Henriksson P. Experimental atherosclerosis: effects of oestrogen and atherosclerosis on thromboxane and prostacyclin formation. Eur J Clin Invest 1990; 20: 105–110.
59. Roselli M, Imthum B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide nitrite/nitrate levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension 1995; 25: 848–853.
60. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992; 263: H271–H259.
61. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynecol 1997; 104: 708–717.
62. Scarabin PY, Gelas M Alhenc, Bureau G Plu, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071–3078.
63. Cangacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992; 74: 1396–1400.
64. Lindheim SR, Duffy DM, Kojima T, Vijod MA, Stanczyk FZ, Lobo RA. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 1994; 62: 1176–1180.
65. Evans SF, Davie MW. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all postmenopausal ages. Clin Endocrinol Oxf 1996; 44: 79–84.
66. Coope J, Thomson J, Poller L. Effects of natural oestrogen replacement therapy on menopausal symptoms and blood clotting. BMJ 1975; 4: 139–143.
67. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case–control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997; 72: 758–761.
68. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147–151.
69. Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458–461.
70. Avila MH, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology 1990; 1: 128–133.
71. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988; 159: 312–317.
72. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991; 325: 756–762.
73. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al The risk of myocardial infarction associated with the combined use of oestrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333–1339.
74. Falkenborn M, Persson I, Adami HO, Bergström R, Eaker E, Lithell H, et al The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynecol 1992; 99: 821–828.
75. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–461.
76. Stampfer MJ, Colditz GA. Estrogen replacement therapy and CHD: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47–63.
77. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–1037.
78. US Congress, Office of Technology Assessment. Effectiveness and costs of osteoporosis screening and hormone replacement therapy. Volume II: Evidence of benefits, risks, and costs. Washington, DC: US Government Printing Office; 1995. OTA-BP-H144.
79. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115: 954–963.
80. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries J. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J 1989; 117: 1209–1214.
81. Sullivan JM, Vander-Zwaag R, Lemp GF, Hughes J, Maddock V, Kroetz DF, et al Postmenopausal estrogen use and coronary atherosclerosis. Ann Int Med 1988; 108: 358–363.
82. Sullivan JM, Vander-Zwaag R, Hughes J, Maddock V, Kroetz DF, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990; 150: 2557–2562.
83. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997; 127: 501–508.
84. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996; 143: 971–978.
85. Connor E Barrett. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991; 115: 455–456.
86. Fuchs-Young R, Glasebrook AL, Short LL, Drapter MW, Rippy MK, Cole HW, et al Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci 1995; 761: 355–360.
87. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–1451.
88. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83: 721–726.
89. Connor E Barrett, Wenger N Kass, Grady D, Mosca L, Collins P, Kornitzer M, et al Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. J Women's Health 1998; 7: 839–847.
90. Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford C, McGowan JA. The evolution of the Women's Heath Initiative: perspectives from the NIH. J Am Med Womens Assoc 1995; 50: 50–55.
91. Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: the case for a randomised controlled trial. Ciba Foundation Symposium 1995; 191: 150–164.